ONYX-II: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Coadministered with Ribavirin in Asian Adults with Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis

被引：0

作者：

Wei, Lai ^{[1
]}

Wang, Qui-Qiang ^{[2
]}

Luo, Yan ^{[3
]}

Chu, Chi-Jen ^{[4
]}

Paik, Seung Woon ^{[5
]}

Hou, Jinlin ^{[6
]}

Cheng, Jun ^{[7
]}

Xie, Qing ^{[8
]}

Duan, Zhongping ^{[9
]}

Kao, Jia-Horng ^{[10
]}

Fu, Bo ^{[3
]}

Mobashery, Niloufar ^{[3
]}

Heo, Jeong ^{[11
,12
]}

机构：

[1] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[2] Peking Univ, Hosp 1, Beijing, Peoples R China

[3] AbbVie Inc, N Chicago, IL USA

[4] Taipei Vet Gen Hosp, Taipei, Taiwan

[5] Samsung Med Ctr, Seoul, South Korea

[6] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China

[7] Capital Med Univ, Beijing Di Tan Hosp, Beijing, Peoples R China

[8] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China

[9] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China

[10] Natl Taiwan Univ Hosp, Zhongzheng Dist, Taiwan

[11] Pusan Natl Univ, Coll Med, Dept Internal Med, Busan, South Korea

[12] Pusan Natl Univ Hosp, Med Res Inst, Busan, South Korea

来源：

HEPATOLOGY | 2016年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

875

引用

页码：434A / 434A

页数：1

共 50 条

[1] Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin in Asian patients with genotype 1b chronic hepatitis C virus infection and compensated cirrhosis: ONYX-II post-treatment week 24 results
Wei, L.
Wang, G. -Q.
Luo, Y.
Chu, C. -J.
Paik, S. W.
Hou, J.
Cheng, J.
Xie, Q.
Duan, Z.
Kao, J. -H.
Fu, B.
Fredrick, L.
Mobashery, N.
Heo, J.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S532 - S532
[2] Changes in markers of liver function in hepatitis C virus genotype 1b Asian patients with compensated cirrhosis treated with ombitasvir/paritaprevir/ritonavir plus dasabuvir with ribavirin in the ONYX-II study
Heo, J.
Luo, Y.
Chuang, W. -L.
Jia, J.
Han, K. -H.
Yu, M. -L.
Tang, H.
Lim, Y. -S.
Peng, C. -Y.
Xu, M.
Wang, M.
Fu, B.
Mobashery, N.
Wei, L.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S517 - S518
[3] Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir with ribavirin in adults with genotype 1 or genotype 4 chronic hepatitis C virus infection and child-pugh B decompensated cirrhosis
Mantry, P.
Reddy, R.
Cohen, E.
Everson, G.
Ramji, A.
Zeuzem, S.
Gordon, S.
Yoshida, E.
Sherman, M.
Balart, L.
Baumgarten, A.
Lee, S.
Fredrick, L. M.
Abunimeh, M.
Cohen, D. E.
Shulman, N. S.
Wilson, J.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S728 - S729
[4] Efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir plus/minus ribavirin for treatment of hepatitis C virus genotype 1b compensated cirrhosis in patients aged 70 years or older
Trifan, A.
Prelipcean, C. C.
Gheorghe, L.
Curescu, M. G.
Brisc, C.
Bataga, S.
Miftode, E.
Arama, V.
Chiriac, S. A.
Cuciureanu, T.
Sporea, I.
Goldis, A.
Popescu, A.
Iacob, S.
Cojocariu, C.
Stefanescu, G.
Girleanu, I.
Mihai, C.
Ciortescu, I.
Stanciu, C.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S284 - S285
[5] Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis
Poordad, Fred
Sedghi, Shahriar
Pockros, Paul J.
Ravendhran, Natarajan
Reindollar, Robert
Lucey, Michael R.
Epstein, Michael
Bank, Leslie
Bernstein, David
Trinh, Roger
Krishnan, Preethi
Polepally, Akshanth R.
Unnebrink, Kristina
Martinez, Marisol
Nelson, David R.
JOURNAL OF VIRAL HEPATITIS, 2019, 26 (08) : 1027 - 1030
[6] ZIRCON: pharmacokinetics, safety, and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in adolescents with genotype 1 or 4 hepatitis C virus infection
Leung, D. H.
Yao, B.
Viani, R. M.
Gonzalez-Peralta, R. P.
Jonas, M. M.
Lobritto, S. J.
Narkewicz, M. R.
Sokal, E.
Fortuny, C.
Hsu, E.
Wirth, S.
Del Valle-Segarra, A.
Zha, J.
Larsen, L.
Liu, L.
Shuster, D. L.
Cohen, D. E.
Rosenthal, P.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S300 - S301
[7] Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older
Trifan, Anca
Stanciu, Carol
Gheorghe, Liana
Iacob, Speranta
Curescu, Manuela
Prelipcean, Cristina Cijevschi
Stefanescu, Gabriela
Girleanu, Irina
Chiriac, Stefan
Mihai, Catalina
Brisc, Ciprian
Goldis, Adrian
Sporea, Ioan
Miftode, Egidia
Bataga, Simona
Rogoveanu, Ion
Preda, Carmen
Caruntu, Florin Alexandru
Singeap, Ana-Maria
MEDICINE, 2017, 96 (50)
[8] Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin (RBV) in hepatitis C virus genotype 1-infected patients with compensated cirrhosis and multiple comorbidities
Popa, R. C.
Mihai, C.
Trifan, A.
Stanciu, C.
Gheorghe, L.
Iacob, S.
Arama, V.
Rogoveanu, I.
Diculescu, M.
Goldis, A.
Bataga, S.
Seicean, A.
Sandulescu, L.
Nastase, R.
Molagic, V.
Brisc, C.
Curescu, M.
Prelipcean, C. C.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S732 - S732
[9] Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
Liu, Chen-Hua
Liu, Chun-Jen
Su, Tung-Hung
Yang, Hung-Chih
Hong, Chun-Ming
Tseng, Tai-Chung
Chen, Pei-Jer
Chen, Ding-Shinn
Kao, Jia-Horng
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (03) : 710 - 717
[10] Efficacy and safety of Ombitasvir/Paritaprevir/Ritonavir+ Dasabuvir and Ribavirin in patients with compensated HCV cirrhosis
Crisu, Georgiana C.
Ionita-Radu, Florentina
Costache, Raluca S.
Balaban, Vasile D.
Nuta, Petrut
Stoica, Victor
Vutcan, L. Oana
Stefan, Ion
Naftanaila, Florica Mali
Jinga, Mariana
ROMANIAN JOURNAL OF MILITARY MEDICINE, 2019, 122 (01) : 22 - 26

← 1 2 3 4 5 →